79. Homozygous familial hypercholesterolemia Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 192 / Drugs : 98 - (DrugBank : 33) / Drug target genes : 12 - Drug target pathways : 21
Homozygous familial hypercholesterolemia and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 79 | Homozygous familial hypercholesterolemia | - |
| 93 | Primary biliary cholangitis | 2.032 |
| 316 | Carnitine cycle disorder | 2.000 |
| 288 | Autoimmune acquired coagulation factor deficiency | 1.333 |
| 94 | Primary sclerosing cholangitis | 1.316 |
| 271 | Ankylosing spondylitis | 1.146 |
| 222 | Primary nephrotic syndrome | 1.098 |
| 84 | Sarcoidosis | 1.073 |
| 299 | Cystic fibrosis | 1.062 |
| 51 | Scleroderma | 1.053 |
| 49 | Systemic lupus erythematosus | 1.053 |
| 97 | Ulcerative colitis | 1.042 |
| 46 | Malignant rheumatoid arthritis | 1.032 |
| 13 | Multiple sclerosis | 1.023 |
| 324 | Methylglutaconic aciduria | 1.000 |
| 317 | Trifunctional protein deficiency | 1.000 |
| 260 | Sitosterolemia | 1.000 |
| 220 | Rapidly progressive glomerulonephritis | 1.000 |
| 30 | Distal myopathy | 1.000 |